8.97
Schlusskurs vom Vortag:
$8.54
Offen:
$8.62
24-Stunden-Volumen:
1.09M
Relative Volume:
1.01
Marktkapitalisierung:
$449.94M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-1.7053
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
-9.03%
1M Leistung:
-4.68%
6M Leistung:
-9.58%
1J Leistung:
-36.43%
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Vergleichen Sie RGNX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RGNX
Regenxbio Inc
|
8.97 | 494.58M | 89.04M | -241.08M | -194.72M | -5.26 |
![]()
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-11 | Herabstufung | Goldman | Buy → Neutral |
2025-02-07 | Fortgesetzt | Raymond James | Outperform |
2024-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
2024-10-10 | Fortgesetzt | Raymond James | Outperform |
2024-06-07 | Eingeleitet | Goldman | Buy |
2024-03-11 | Eingeleitet | H.C. Wainwright | Buy |
2024-03-08 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2024-03-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-02-21 | Fortgesetzt | Raymond James | Outperform |
2023-11-01 | Eingeleitet | Stifel | Buy |
2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
2022-06-23 | Eingeleitet | Berenberg | Buy |
2021-12-15 | Eingeleitet | Wedbush | Neutral |
2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
2020-12-16 | Eingeleitet | UBS | Buy |
2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
2019-06-14 | Fortgesetzt | Raymond James | Outperform |
2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
2018-05-09 | Bestätigt | Barclays | Overweight |
2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
2018-02-13 | Eingeleitet | Mizuho | Neutral |
2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa
REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.
Regenxbio at RBC Conference: Strategic Moves and Clinical Progress - Investing.com Australia
Regenxbio at RBC Conference: Strategic Moves and Clinical Progress By Investing.com - Investing.com Nigeria
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million | RGNX Stock News - GuruFocus
Stifel maintains Buy on Regenxbio, price target at $40 By Investing.com - Investing.com Nigeria
Stifel maintains Buy on Regenxbio, price target at $40 - Investing.com
Regenxbio Secures $250 Million In New Royalty Bonds - Finimize
REGENXBIO secures $150 million to extend cash runway By Investing.com - Investing.com South Africa
Regenxbio (RGNX) Secures $250M Royalty Bond Deal for Non-Dilutiv - GuruFocus
REGENXBIO (RGNX) Secures $250 Million Non-Dilutive Funding - GuruFocus
REGENXBIO secures $150 million to extend cash runway - Investing.com Australia
RegenXBio Secures $250M Royalty Monetization Deal - TipRanks
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million - Eagle-Tribune
Regenxbio Announces Strategic Royalty Monetization Agreement For Up To $250 Million - marketscreener.com
REGENXBIO's $250M Royalty Deal Extends Cash Runway to 2027, Funds Multiple Late-Stage Programs - Stock Titan
Regenxbio signals RGX-202 pivotal enrollment surpasses 50% as company initiates commercial manufacturing in Q3 2025 - MSN
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year - TipRanks
REGENXBIO’s BLA for MPS II Gene Therapy RGX-121 Accepted for Priority Review by the FDA - CGTLive®
REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next - simplywall.st
Regenxbio BLA for Hunter syndrome candidate accepted by FDA - MSN
(RGNX) Proactive Strategies - news.stocktradersdaily.com
Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Call Transcript - Insider Monkey
FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy fo - GuruFocus
FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment - marketscreener.com
FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy for MPS II | RGNX Stock News - GuruFocus
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - Eastern Progress
US FDA accepts Regenxbio’s application for MPS II gene therapy - World Pharmaceutical Frontiers
Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises By Investing.com - Investing.com Nigeria
Stifel maintains buy on Regenxbio, reiterates $40 target - Investing.com Australia
Regenxbio (RGNX) Gains FDA Priority Review for RGX-121 BLA | RGN - GuruFocus
Transcript : REGENXBIO Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com
Stifel maintains buy on Regenxbio, reiterates $40 target By Investing.com - Investing.com India
REGENXBIO (RGNX) Reports Decrease in Q1 Revenue, Focuses on Gene Therapy Progress | RGNX Stock News - GuruFocus
REGENXBIO Reports First Quarter 2025 Financial Results and Recen - GuruFocus
Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review - marketscreener.com
Regenxbio stock rises on FDA’s priority review for MPS II therapy - Investing.com Nigeria
Regenxbio stock rises on FDA’s priority review for MPS II therapy By Investing.com - Investing.com South Africa
Regenxbio Announces FDA Acceptance And Priority Review Of BLA For Rgx-121 For Mps Ii - marketscreener.com
REGENXBIO Announces FDA Acceptance and Priority Review of the BL - GuruFocus
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):